For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

The bad news is you have ductal carcinoma in situ. The good news is that DCIS is the best type of breast cancer to get.

A study explores how prior authorization requirements; coverage stoppages and other red tape can generate barriers to life ...

I was diagnosed with follicular lymphoma in 2020, during COVID, which forced me to retire early and taught me I’m more than a ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...